User contributions for Edzelco

03:2103:21, 20 April 2024 diff hist +31‎ User:Edzelco ‎ →‎Pages Authored/Co-authored/Collaborated current
03:2003:20, 20 April 2024 diff hist +38,269‎ Cipaglucosidase alfa-atga ‎No edit summary current

12:4812:48, 18 April 2024 diff hist +96‎ User:Edzelco ‎ →‎Pages Authored/Co-authored/Collaborated
12:4512:45, 18 April 2024 diff hist −220‎ Momelotinib ‎No edit summary current
12:4412:44, 18 April 2024 diff hist +34,290‎ Momelotinib ‎No edit summary
12:1212:12, 18 April 2024 diff hist +26,053‎ Motixafortide ‎No edit summary current
11:4911:49, 18 April 2024 diff hist +2,390‎ Pozelimab-bbfg ‎No edit summary current
11:4211:42, 18 April 2024 diff hist +39,181‎ Palovarotene ‎No edit summary current
11:1611:16, 18 April 2024 diff hist +32,847‎ Elranatamab-bcmm ‎No edit summary current

08:0808:08, 17 April 2024 diff hist +53‎ N Elranatamab-bcmm ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}"
08:0808:08, 17 April 2024 diff hist +53‎ N Palovarotene ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}"
08:0808:08, 17 April 2024 diff hist +53‎ N Pozelimab-bbfg ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}"
08:0708:07, 17 April 2024 diff hist +53‎ N Motixafortide ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}"
08:0708:07, 17 April 2024 diff hist +53‎ N Momelotinib ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}"
08:0608:06, 17 April 2024 diff hist +53‎ N Cipaglucosidase alfa-atga ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}"
08:0508:05, 17 April 2024 diff hist +53‎ N Etrasimod ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}" current
08:0508:05, 17 April 2024 diff hist +53‎ N Zilucoplan ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}" current
08:0408:04, 17 April 2024 diff hist +53‎ N Bimekizumab ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}" current
08:0408:04, 17 April 2024 diff hist +53‎ N Vamorolone ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}" current
08:0408:04, 17 April 2024 diff hist +53‎ N Mirikizumab-mrkz ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}" current
08:0308:03, 17 April 2024 diff hist +53‎ N Toripalimab-tpzi ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}" current
08:0208:02, 17 April 2024 diff hist +18‎ User:Edzelco ‎ →‎Pages Authored/Co-authored/Collaborated
08:0208:02, 17 April 2024 diff hist +25,648‎ N Fruquintinib ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=fruquintinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy |fdaLIADAdult=Recommended Dosage The recommended dose of F..." current
07:5307:53, 17 April 2024 diff hist +26‎ User:Edzelco ‎ →‎Pages Authored/Co-authored/Collaborated
07:5307:53, 17 April 2024 diff hist 0‎ Taurolidine, heparin ‎No edit summary current
07:5207:52, 17 April 2024 diff hist +9,993‎ N Taurolidine, heparin ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{Edzelco}} |genericName=taurolidine, heparin |aOrAn=a |drugClass=combination of taurolidine, a thiadiazinane antimicrobial, and heparin, an anti-coagulant |indicationType=prevention |indication=atheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients..."
07:4407:44, 17 April 2024 diff hist 0‎ User:Edzelco ‎ →‎Pages Authored/Co-authored/Collaborated
07:4407:44, 17 April 2024 diff hist +36‎ User:Edzelco ‎ →‎Pages Authored/Co-authored/Collaborated
07:4307:43, 17 April 2024 diff hist +19‎ User:Edzelco ‎ →‎Pages Authored/Co-authored/Collaborated
07:4307:43, 17 April 2024 diff hist +32,783‎ N Repotrectinib ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=repotrectinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) |contraindications=None |warnings=5.1 Central Nervous System Adverse Reactions AUGTYRO can cause central nervous system adverse reactions. Among the 351 patients who received AUGTYRO in Study TRIDENT-1, a broad spectru..." current
07:3407:34, 17 April 2024 diff hist 0‎ Efbemalenograstim alfa-vuxw ‎No edit summary current
07:3307:33, 17 April 2024 diff hist +51‎ Efbemalenograstim alfa-vuxw ‎No edit summary
07:3207:32, 17 April 2024 diff hist +20,075‎ N Efbemalenograstim alfa-vuxw ‎ Created page with "{{DrugProjectFormSinglePage |genericName=efbemalenograstim alfa-vuxw |aOrAn=a |drugClass=leukocyte growth factor |indicationType=prevention |indication=incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia |fdaLIADAdult=Recommended Dose: 20 mg administered subcutaneously once per chemotherapy cycle...."

05:5005:50, 16 April 2024 diff hist +18‎ User:Edzelco ‎ →‎Pages Authored/Co-authored/Collaborated
05:5005:50, 16 April 2024 diff hist +34,175‎ N Capivasertib ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Capivasertib |aOrAn=a |drugClass=kinase inhibitor in combination with fulvestrant |indicationType=treatment |indication=adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based..." current
05:2805:28, 16 April 2024 diff hist +15‎ User:Edzelco ‎ →‎Pages Authored/Co-authored/Collaborated
05:2705:27, 16 April 2024 diff hist +33,311‎ N Iptacopan ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=iptacopan |aOrAn=a |drugClass=complement factor B inhibitor |indicationType=treatment |indication=paroxysmal nocturnal hemoglobinuria |blackBoxWarningTitle=WARNING: SERIOUS INFECTIONS CAUSED BY ENCAPSULATED BACTERIA |blackBoxWarningBody= FABHALTA increases the risk of serious and life-threatening infections caused by encapsulated bacteria, including Streptococcus pneumoniae, Neisseria me..." current

07:2507:25, 15 April 2024 diff hist +16‎ User:Edzelco ‎ →‎Pages Authored/Co-authored/Collaborated
07:2407:24, 15 April 2024 diff hist +17,228‎ N Vutrisiran ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=vutrisiran |aOrAn=a |drugClass=transthyretin-directed small interfering RNA |indicationType=treatment |indication=polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. |adverseReactions=pain in extremity, arthralgia, dyspnea, and decreased vitamin A levels. |fdaLIADAdult=Recommended Dosage The recommended dosage of AMVUTTRA is 25 mg administered by subcutaneous inj..." current

07:0907:09, 24 March 2024 diff hist 0‎ User:Edzelco ‎ →‎Peer Reviewed Journal Articles/Abstracts

03:1503:15, 18 February 2024 diff hist −58‎ User:Edzelco ‎No edit summary

22:2422:24, 11 February 2024 diff hist +16‎ User:Edzelco ‎ →‎Pages Authored/Co-authored/Collaborated
22:2322:23, 11 February 2024 diff hist +1,081‎ N Mavacamten ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=mavacamten |aOrAn=a |drugClass=cardiac myosin inhibitor |indicationType=treatment |indication=adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms |hasBlackBoxWarning=Yes |adverseReactions=dizziness (27%) and syncope (6%) |blackBoxWarningTitle=WARNING: RISK OF HEART..." current
00:4200:42, 11 February 2024 diff hist −258‎ User:Edzelco ‎ →‎Peer Reviewed Journal Articles/Abstracts (Other than Published)
00:4000:40, 11 February 2024 diff hist +396‎ User:Edzelco ‎ →‎Peer Reviewed Journal Articles/Abstracts
00:3900:39, 11 February 2024 diff hist −207‎ User:Edzelco ‎ →‎Peer Reviewed Journal Articles/Abstracts (Other than Published)

19:0519:05, 10 February 2024 diff hist +19‎ User:Edzelco ‎ →‎Pages Authored/Co-authored/Collaborated
19:0519:05, 10 February 2024 diff hist +23‎ Oteseconazole ‎No edit summary current
19:0419:04, 10 February 2024 diff hist +25,740‎ N Oteseconazole ‎ Created page with "{{DrugProjectFormSinglePage |genericName=oteseconazole |aOrAn=an |drugClass=azole antifungal |indicationType=prevention |indication=recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are NOT of reproductive potential |adverseReactions=headache and nausea |fdaLIADAdult=VIVJOA Capsules: 150 mg of oteseconazole in lavender hard gelatin capsules imprinted with OTE 150 in black ink. Fluconazole is not supplied in the carton. |co..."
19:0219:02, 10 February 2024 diff hist 0‎ N File:VIVJOA label3.png ‎No edit summary current
19:0219:02, 10 February 2024 diff hist 0‎ N File:VIVJOA label2.png ‎No edit summary current
19:0219:02, 10 February 2024 diff hist 0‎ N File:VIVJOA label.png ‎No edit summary current
19:0219:02, 10 February 2024 diff hist 0‎ N File:VIVJOA structure.png ‎No edit summary current
18:4718:47, 10 February 2024 diff hist −18‎ User:Edzelco ‎ →‎Edzel Lorraine Co, DMD, MD

00:4700:47, 7 February 2024 diff hist 0‎ User:Edzelco ‎ →‎Pages Authored/Co-authored/Collaborated
00:4700:47, 7 February 2024 diff hist +44‎ User:Edzelco ‎ →‎Pages Authored/Co-authored/Collaborated
00:4700:47, 7 February 2024 diff hist +25,546‎ N Lutetium (177Lu) vipivotide tetraxetan ‎ Created page with "{{DrugProjectFormSinglePage |genericName=lutetium (177Lu) vipivotide tetraxetan |aOrAn=a |drugClass=radioligand therapeutic agent |indicationType=treatment |indication=adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy |adverseReactions=fatigue, dry mout..." current
00:4400:44, 7 February 2024 diff hist 0‎ N File:Pluvicto label.png ‎No edit summary current
00:4400:44, 7 February 2024 diff hist 0‎ N File:Pluvicto structure.png ‎No edit summary current

00:5700:57, 6 February 2024 diff hist +35‎ User:Edzelco ‎ →‎Pages Authored/Co-authored/Collaborated
00:5700:57, 6 February 2024 diff hist +33,106‎ N Nivolumab and relatlimab-rmbw ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=nivolumab and relatlimab-rmbw |aOrAn=a |drugClass=combination of nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody |indicationType=treatment |indication=adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma |adverseReactions=immune-mediated pneumonitis, im..." current
00:5600:56, 6 February 2024 diff hist 0‎ N File:Nivolumab and relatlimab-rmbw label.png ‎No edit summary current
00:2600:26, 6 February 2024 diff hist +16‎ User:Edzelco ‎ →‎Pages Authored/Co-authored/Collaborated
00:2300:23, 6 February 2024 diff hist −2‎ Ganaxolone ‎No edit summary current
00:2300:23, 6 February 2024 diff hist +24,999‎ Ganaxolone ‎No edit summary
00:2200:22, 6 February 2024 diff hist 0‎ N File:Ganaloxone bottle carton.png ‎No edit summary current
00:2200:22, 6 February 2024 diff hist 0‎ N File:Ganaloxone bottle suspension label 50mg.png ‎No edit summary current
00:2100:21, 6 February 2024 diff hist 0‎ N File:Ganaloxone structure.png ‎No edit summary current

15:4915:49, 2 February 2024 diff hist 0‎ User:Edzelco ‎ →‎Pages Authored/Co-authored/Collaborated
15:4915:49, 2 February 2024 diff hist +16‎ User:Edzelco ‎ →‎Pages Authored/Co-authored/Collaborated
15:4815:48, 2 February 2024 diff hist −2‎ Pacritinib ‎No edit summary current
15:4715:47, 2 February 2024 diff hist +29,299‎ N Pacritinib ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Pacritinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L (1) |adverseReactions=diarrhea, thrombocytopenia, nausea, anemia, and peripheral edema |fdaLIADAdult=The recommended dosage of VONJO is 200 mg orally twi..."
15:4715:47, 2 February 2024 diff hist 0‎ N File:Pacritinib Bottle Label.png ‎No edit summary current
15:4715:47, 2 February 2024 diff hist 0‎ N File:Pacritinib Carton Label.png ‎No edit summary current
15:4715:47, 2 February 2024 diff hist 0‎ N File:Pacritinib supply.png ‎No edit summary current
15:4715:47, 2 February 2024 diff hist 0‎ N File:Pacritinib structure.png ‎No edit summary current

16:5316:53, 1 February 2024 diff hist 0‎ User:Edzelco ‎ →‎Pages Authored/Co-authored/Collaborated
16:5316:53, 1 February 2024 diff hist 0‎ User:Edzelco ‎ →‎Pages Authored/Co-authored/Collaborated
16:5216:52, 1 February 2024 diff hist +15‎ User:Edzelco ‎ →‎Pages Authored/Co-authored/Collaborated
16:5216:52, 1 February 2024 diff hist +22,285‎ Mitapivat ‎No edit summary current
16:2316:23, 1 February 2024 diff hist −23,245‎ Mitapivat ‎ Blanked the page Tag: Blanking
16:2216:22, 1 February 2024 diff hist +1,030‎ Mitapivat ‎ Undo revision 1736932 by Edzelco (talk) Tag: Undo
16:2216:22, 1 February 2024 diff hist −1,030‎ Mitapivat ‎No edit summary
16:2116:21, 1 February 2024 diff hist −16‎ Mitapivat ‎No edit summary
16:2016:20, 1 February 2024 diff hist −36‎ Mitapivat ‎No edit summary
16:1916:19, 1 February 2024 diff hist +461‎ Mitapivat ‎ Undo revision 1736928 by Edzelco (talk) Tag: Undo
16:1916:19, 1 February 2024 diff hist −461‎ Mitapivat ‎No edit summary
16:1616:16, 1 February 2024 diff hist −4‎ Mitapivat ‎No edit summary Tag: Manual revert
16:1616:16, 1 February 2024 diff hist +4‎ Mitapivat ‎No edit summary
16:1416:14, 1 February 2024 diff hist −2‎ Mitapivat ‎No edit summary Tag: Manual revert
16:1416:14, 1 February 2024 diff hist +2‎ Mitapivat ‎No edit summary
16:1316:13, 1 February 2024 diff hist +23,297‎ N Mitapivat ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=mitapivat |aOrAn=a |drugClass=pyruvate kinase activator |indicationType=treatment |indication=hemolytic anemia in adults with pyruvate kinase (PK) deficiency |adverseReactions=estrone decreased (males), increased urate, back pain, estradiol decreased (males), and arthralgia |fdaLIADAdult=PYRUKYND is taken with or without food and swallowed whole. Do not split, crush, chew,..."
16:0816:08, 1 February 2024 diff hist 0‎ N File:Mitapivat 5mg.png ‎No edit summary current
16:0816:08, 1 February 2024 diff hist 0‎ N File:Mitapivat 5mg tablet blister pack.png ‎No edit summary current
16:0716:07, 1 February 2024 diff hist 0‎ N File:Mitapivat 20mg.png ‎No edit summary current
16:0716:07, 1 February 2024 diff hist 0‎ N File:Mitapivat 20mg tablet blister pack.png ‎No edit summary current
16:0716:07, 1 February 2024 diff hist 0‎ N File:Mitapivat 50mg.png ‎No edit summary current
16:0716:07, 1 February 2024 diff hist 0‎ N File:Mitapivat 50mg tablet blister pack.png ‎No edit summary current
16:0616:06, 1 February 2024 diff hist 0‎ N File:Mitapivat structure.png ‎No edit summary current
16:0616:06, 1 February 2024 diff hist 0‎ N File:Mitapivat supply.png ‎No edit summary current
15:4615:46, 1 February 2024 diff hist +21‎ User:Edzelco ‎ →‎Pages Authored/Co-authored/Collaborated
15:4615:46, 1 February 2024 diff hist +26,967‎ N Sutimlimab-jome ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Sutimlimab-jome |aOrAn=a |drugClass=classical complement inhibitor |indicationType=treatment |indication=hemolysis in adults with cold agglutinin disease (CAD) |adverseReactions=in the CADENZA study (Part A) (incidence ≥18%) are rhinitis, headache, hypertension, acrocyanosis, and Raynaud's phenomenon. The most common adverse reactions in the CARDINAL study (incidence ≥..." current
15:4415:44, 1 February 2024 diff hist 0‎ N File:Sutimlimab-jome packaging.png ‎No edit summary current
15:3215:32, 1 February 2024 diff hist +20‎ User:Edzelco ‎No edit summary
15:3115:31, 1 February 2024 diff hist +24,023‎ N Faricimab-svoa ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Faricimab-svoa |aOrAn=a |drugClass=vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2) inhibitor |indicationType=treatment |indication=patients with neovascular (wet) age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO) |adverseReactions=cataract (15%) and [[conjunctival hemorrhage]..." current
15:0515:05, 1 February 2024 diff hist +32‎ User:Edzelco ‎ →‎Pages Authored/Co-authored/Collaborated
15:0515:05, 1 February 2024 diff hist −1‎ User:Edzelco ‎ →‎Pages Authored/Co-authored/Collaborated
15:0415:04, 1 February 2024 diff hist +25‎ User:Edzelco ‎ →‎Pages Authored/Co-authored/Collaborated
15:0415:04, 1 February 2024 diff hist +17‎ User:Edzelco ‎ →‎Pages Authored/Co-authored/Collaborated
15:0315:03, 1 February 2024 diff hist +16‎ User:Edzelco ‎ →‎Pages Authored/Co-authored/Collaborated
15:0315:03, 1 February 2024 diff hist +31‎ User:Edzelco ‎ →‎Pages Authored/Co-authored/Collaborated
15:0215:02, 1 February 2024 diff hist +31‎ User:Edzelco ‎ →‎Pages Authored/Co-authored/Collaborated
15:0215:02, 1 February 2024 diff hist +18‎ User:Edzelco ‎ →‎Pages Authored/Co-authored/Collaborated
15:0115:01, 1 February 2024 diff hist +18‎ User:Edzelco ‎ →‎Pages Authored/Co-authored/Collaborated
15:0015:00, 1 February 2024 diff hist +17‎ User:Edzelco ‎ →‎Pages Authored/Co-authored/Collaborated
15:0015:00, 1 February 2024 diff hist +22‎ User:Edzelco ‎ →‎Pages Authored/Co-authored/Collaborated
14:5914:59, 1 February 2024 diff hist +18,438‎ N Tebentafusp-tebn ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Tebentafusp-tebn |aOrAn=a |drugClass=bispecific gp100 peptide-HLA-directed CD3 T cell engager |indicationType=treatment |indication=HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma |hasBlackBoxWarning=Yes |adverseReactions=cytokine release syndrome, rash, pyrexia, pruritus, fatigue, nausea, chills, abdominal pain, edema, hypotension, dry skin, headache and vomiting. The most..." current
01:4901:49, 1 February 2024 diff hist +604‎ Abrocitinib ‎No edit summary current
01:4601:46, 1 February 2024 diff hist +13,636‎ Abrocitinib ‎No edit summary
01:4601:46, 1 February 2024 diff hist 0‎ N File:Abrocitinib 200mg.png ‎No edit summary current
01:4601:46, 1 February 2024 diff hist 0‎ N File:Abrocitinib 100mg.png ‎No edit summary current
01:4301:43, 1 February 2024 diff hist 0‎ N File:Abrocitinib 50mg.png ‎No edit summary current
01:3901:39, 1 February 2024 diff hist 0‎ N File:Abrocitinib supply.png ‎No edit summary current
01:3201:32, 1 February 2024 diff hist 0‎ N File:Abrocitinib.png ‎No edit summary current
01:3101:31, 1 February 2024 diff hist +22,842‎ N Abrocitinib ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |indicationType=treatment |indication=adults and pediatric patients 12 years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable. |blackBoxWarningTitle=WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), and THROMBOS..."
01:0601:06, 1 February 2024 diff hist −279‎ Daridorexant ‎No edit summary current

21:1721:17, 31 January 2024 diff hist +31,199‎ N Daridorexant ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=daridorexant |aOrAn=an |drugClass=orexin receptor antagonist |indicationType=treatment |indication=adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance |adverseReactions=Common adverse reactions (reported in ≥ 5% of patients treated with QUVIVIQ and at an incidence ≥ than placebo) include headache and somnolence or fatigue..."
21:1521:15, 31 January 2024 diff hist 0‎ N File:Clinical Studies 3.png ‎No edit summary current
21:1521:15, 31 January 2024 diff hist 0‎ N File:Clinical Studies 2.png ‎No edit summary current
21:1521:15, 31 January 2024 diff hist 0‎ N File:Clinical Studies 1.png ‎No edit summary current
21:0721:07, 31 January 2024 diff hist 0‎ N File:Effects of hepatic impairment and renal impairment on daridorexant PK.png ‎No edit summary current
21:0721:07, 31 January 2024 diff hist 0‎ N File:Effect of daridorexant on the PK of other compounds.png ‎No edit summary current
21:0621:06, 31 January 2024 diff hist 0‎ N File:Effect of co-administered compounds on the PK of daridorexant.png ‎No edit summary current
21:0121:01, 31 January 2024 diff hist 0‎ N File:Packaging 3.png ‎No edit summary current
21:0121:01, 31 January 2024 diff hist 0‎ N File:Packaging 2.png ‎No edit summary current
21:0021:00, 31 January 2024 diff hist 0‎ N File:Packaging 1.png ‎No edit summary current
20:4920:49, 31 January 2024 diff hist 0‎ N File:Daridorexant.png ‎No edit summary current

00:2500:25, 25 January 2024 diff hist +5,566‎ N Orbifloxacin ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Orbifloxacin |aOrAn=a |drugClass=fluoroquinolone carboxylic acid derivatives |indicationType=treatment |indication=urinary tract infections (cystitis) in dogs caused by susceptible strains of Staphylococcus pseudintermedius, Proteus mirabilis, Escherichia coli and Enterococcus faecalis. |adverseReactions=In a field study, when the tablet formulation of orbifloxacin..." current
00:1600:16, 25 January 2024 diff hist 0‎ N File:Orbifloxacin packaging.png ‎No edit summary current
00:1500:15, 25 January 2024 diff hist 0‎ N File:Orbifloxacin suspension 2.png ‎No edit summary current
00:1500:15, 25 January 2024 diff hist 0‎ N File:Orbifloxacin suspension.png ‎No edit summary current
00:1500:15, 25 January 2024 diff hist 0‎ N File:Orbifloxacin structure.png ‎No edit summary current

14:2814:28, 23 January 2024 diff hist +30,972‎ N Ado-Trastuzumab Emtansine ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Ado-trastuzumab emtansine |aOrAn=a |drugClass=HER2-targeted antibody and microtubule inhibitor conjugate |indicationType=treatment |indication=1.) patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: a.) Received prior therapy for metastatic disease, or b.) Developed disease recurrence during or wi..." current
14:2414:24, 23 January 2024 diff hist 0‎ N File:Ado-trastuzumab emtansine packaging 160mg.png ‎No edit summary current
14:2214:22, 23 January 2024 diff hist 0‎ N File:Ado-trastuzumab emtansine packaging.png ‎No edit summary current
14:1914:19, 23 January 2024 diff hist 0‎ N File:Ado-trastuzumab emtansine supply.png ‎No edit summary current
14:1914:19, 23 January 2024 diff hist 0‎ N File:Ado-trastuzumab emtansine structure.png ‎No edit summary current

23:3223:32, 22 January 2024 diff hist +17,319‎ N Omacetaxine mepesuccinate ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Omacetaxine mepesuccinate (SYNRIBO) |aOrAn=an |drugClass=injection |indicationType=treatment |indication=adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI) |fdaLIADAdult=*Induction Dose: 1.25 mg/m2 administered by subcutaneous injection twice daily for 14 consecutive days of a 28-day cycle. *Maint..." current
23:0823:08, 22 January 2024 diff hist +1,322‎ N Adipiodone ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Adipiodone meglumine |aOrAn=a |drugClass=a tri-iodinated benzoate derivative and an ionic dimeric contrast agent |indicationType=procedure |indication=diagnostic imaging, as this agent blocks x-ray and appears opaque on x-ray film; thereby it enhances the visibility of the bile ducts and gallbladder during cholangiography and cholecystography procedures |adverseReactions=epilepsy, abdominal pain, and tremor..." current
21:1721:17, 22 January 2024 diff hist 0‎ N File:Adipiodine FDA-Approved Drugs.png ‎No edit summary current
21:1221:12, 22 January 2024 diff hist 0‎ N File:Structure of Adipiodine.png ‎No edit summary current
16:4316:43, 22 January 2024 diff hist +1,686‎ Oclacitinib ‎No edit summary current
16:4216:42, 22 January 2024 diff hist 0‎ N File:Oclatinib.png ‎No edit summary current
16:3716:37, 22 January 2024 diff hist +3,415‎ N Oclacitinib ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |aOrAn=an |drugClass=immunomodulator |indicationType=treatment |indication=pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age |blackBoxWarningBody=This product is not for human use. Keep this and all drugs out of reach of children. For use in dogs only. Wash hands immediately after handling the tablets. In case of accidental eye contact, flush immediately with..."
16:3416:34, 22 January 2024 diff hist 0‎ N File:APOQUEL tablets 16 mg Tablet Bottle Label.png ‎No edit summary current
16:3416:34, 22 January 2024 diff hist 0‎ N File:APOQUEL tablets 5.4 mg Tablet Bottle Label.png ‎No edit summary current
16:3416:34, 22 January 2024 diff hist 0‎ N File:APOQUEL tablets 3.6 mg Tablet Bottle Label.png ‎No edit summary current
15:4915:49, 22 January 2024 diff hist +331‎ N Absorbable gelatin sponge ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Gelatin Sponge, Absorbable |aOrAn=a |drugClass=sterile, gelatin-base surgical sponge |indicationType=treatment |indication=bleeding as an adjunct to hemostasis when conventional procedure is ineffective. |brandNames=*Gelfoam |lookAlike=*Gelaspon *SurgiFoam }}" current
15:2515:25, 22 January 2024 diff hist +1‎ AbobotulinumtoxinA ‎No edit summary current
15:2415:24, 22 January 2024 diff hist +2‎ AbobotulinumtoxinA ‎No edit summary
15:2415:24, 22 January 2024 diff hist 0‎ AbobotulinumtoxinA ‎No edit summary
15:2215:22, 22 January 2024 diff hist −4‎ AbobotulinumtoxinA ‎No edit summary
15:2015:20, 22 January 2024 diff hist −6‎ Allergy medical therapy ‎ →‎Contraindicated Medications current
15:2015:20, 22 January 2024 diff hist +111‎ Allergy medical therapy ‎No edit summary
02:3002:30, 22 January 2024 diff hist +21‎ AbobotulinumtoxinA ‎No edit summary
01:3701:37, 22 January 2024 diff hist +167‎ AbobotulinumtoxinA ‎ Undo revision 1736837 by Edzelco (talk) Tag: Undo
01:3701:37, 22 January 2024 diff hist −167‎ AbobotulinumtoxinA ‎No edit summary
01:3301:33, 22 January 2024 diff hist −6‎ AbobotulinumtoxinA ‎No edit summary Tag: Manual revert
01:3201:32, 22 January 2024 diff hist +6‎ AbobotulinumtoxinA ‎No edit summary
01:3201:32, 22 January 2024 diff hist +9‎ AbobotulinumtoxinA ‎No edit summary
01:3001:30, 22 January 2024 diff hist +7‎ AbobotulinumtoxinA ‎No edit summary
01:2701:27, 22 January 2024 diff hist −28‎ AbobotulinumtoxinA ‎No edit summary
01:2501:25, 22 January 2024 diff hist 0‎ AbobotulinumtoxinA ‎No edit summary
01:2501:25, 22 January 2024 diff hist 0‎ AbobotulinumtoxinA ‎No edit summary
01:2301:23, 22 January 2024 diff hist −6‎ AbobotulinumtoxinA ‎No edit summary
01:2201:22, 22 January 2024 diff hist +77‎ AbobotulinumtoxinA ‎No edit summary
01:1501:15, 22 January 2024 diff hist −22‎ AbobotulinumtoxinA ‎No edit summary
01:1001:10, 22 January 2024 diff hist +92‎ 2-(4-chlorphenoxy)-ethanol ‎No edit summary current
01:0701:07, 22 January 2024 diff hist +183‎ 2-(4-chlorphenoxy)-ethanol ‎No edit summary
01:0401:04, 22 January 2024 diff hist −1‎ 2-(4-chlorphenoxy)-ethanol ‎No edit summary
01:0301:03, 22 January 2024 diff hist +24‎ 2-(4-chlorphenoxy)-ethanol ‎No edit summary
00:5900:59, 22 January 2024 diff hist −50‎ 2-(4-chlorphenoxy)-ethanol ‎No edit summary
00:5800:58, 22 January 2024 diff hist −126‎ 2-(4-chlorphenoxy)-ethanol ‎No edit summary
00:4400:44, 22 January 2024 diff hist +413‎ 2-(4-chlorphenoxy)-ethanol ‎No edit summary
00:2600:26, 22 January 2024 diff hist +1,249‎ 2-(4-chlorphenoxy)-ethanol ‎No edit summary
00:2100:21, 22 January 2024 diff hist +112‎ 2-(4-chlorphenoxy)-ethanol ‎No edit summary
00:2100:21, 22 January 2024 diff hist 0‎ N File:2-(4-CHLOROPHENOXY)ETHANOL.png ‎No edit summary current
00:1300:13, 22 January 2024 diff hist −4‎ AbobotulinumtoxinA ‎No edit summary
00:1200:12, 22 January 2024 diff hist −130‎ AbobotulinumtoxinA ‎No edit summary
00:1000:10, 22 January 2024 diff hist −4‎ AbobotulinumtoxinA ‎No edit summary
00:0900:09, 22 January 2024 diff hist +138‎ AbobotulinumtoxinA ‎ Undo revision 1736812 by Edzelco (talk) Tag: Undo
00:0700:07, 22 January 2024 diff hist −138‎ AbobotulinumtoxinA ‎No edit summary
00:0100:01, 22 January 2024 diff hist +25‎ AbobotulinumtoxinA ‎No edit summary

23:5823:58, 21 January 2024 diff hist −5‎ AbobotulinumtoxinA ‎No edit summary
23:5123:51, 21 January 2024 diff hist +29,225‎ AbobotulinumtoxinA ‎No edit summary
22:1822:18, 21 January 2024 diff hist +3‎ AbobotulinumtoxinA ‎No edit summary
22:1622:16, 21 January 2024 diff hist +821‎ N AbobotulinumtoxinA ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Dysport |indication=Dysport is FDA approved for the treatment of cervical dystonia in adults, improvement of moderate to severe frown lines on the glabellar zone (eyebrows) of adults aged 65 years old or younger for a short period of time, and spasticity in people aged 2 years or older. |adverseReactions=Common adverse reactions include difficulty in breathing, speak..."
21:3021:30, 21 January 2024 diff hist +53‎ 2-(4-chlorphenoxy)-ethanol ‎No edit summary
21:2921:29, 21 January 2024 diff hist −42‎ 2-(4-chlorphenoxy)-ethanol ‎ Blanked the page Tag: Blanking
21:2921:29, 21 January 2024 diff hist −20‎ 2-(4-chlorphenoxy)-ethanol ‎No edit summary
21:2821:28, 21 January 2024 diff hist +62‎ N 2-(4-chlorphenoxy)-ethanol ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{CMG}}; {{EdzelCo}} }}"
01:0701:07, 21 January 2024 diff hist +13,116‎ Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy ‎ /* 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy {{cite journal| author=Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P | display-authors=etal| title=2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. | journal=Circulation | year= 2020 | volu... current
00:4300:43, 21 January 2024 diff hist +4,518‎ Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy ‎ /* 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy {{cite journal| author=Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P | display-authors=etal| title=2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. | journal=Circulation | year= 2020 | volu...
00:3400:34, 21 January 2024 diff hist +104‎ Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy ‎ →‎Recommendations for the Management of Patients With HCM and Ventricular Arrhythmias
00:3400:34, 21 January 2024 diff hist −102‎ Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy ‎ →‎Recommendations for the Management of Patients With HCM and Ventricular Arrhythmias Tag: Visual edit
00:3200:32, 21 January 2024 diff hist +9‎ Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy ‎ →‎Recommendations for the Management of Patients With HCM and Ventricular Arrhythmias
00:3200:32, 21 January 2024 diff hist −6‎ Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy ‎ →‎Recommendations for the Management of Patients With HCM and Ventricular Arrhythmias
00:3100:31, 21 January 2024 diff hist 0‎ Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy ‎ →‎Recommendations for the Management of Patients With HCM and Ventricular Arrhythmias
00:3000:30, 21 January 2024 diff hist +156‎ Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy ‎ →‎Recommendations for the Management of Patients With HCM and Ventricular Arrhythmias
00:2900:29, 21 January 2024 diff hist +7‎ Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy ‎ →‎Recommendations for the Management of Patients With HCM and Ventricular Arrhythmias
00:2800:28, 21 January 2024 diff hist −39‎ Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy ‎ →‎Recommendations for the Management of Patients With HCM and Ventricular Arrhythmias Tag: Visual edit
00:2700:27, 21 January 2024 diff hist +10,642‎ Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy ‎ /* 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy {{cite journal| author=Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P | display-authors=etal| title=2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. | journal=Circulation | year= 2020 | volu...
00:0100:01, 21 January 2024 diff hist +4,658‎ Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy ‎ /* 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy {{cite journal| author=Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P | display-authors=etal| title=2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. | journal=Circulation | year= 2020 | volu...

23:4923:49, 20 January 2024 diff hist +7‎ Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy ‎ →‎Recommendations for Pharmacologic Management of Patients With Obstructive HCM
23:4823:48, 20 January 2024 diff hist +68‎ Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy ‎ →‎Recommendations for Pharmacologic Management of Patients With Obstructive HCM
23:4723:47, 20 January 2024 diff hist +18‎ Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy ‎ →‎Recommendations for Pharmacologic Management of Patients With Obstructive HCM Tag: Visual edit
23:4623:46, 20 January 2024 diff hist −58‎ Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy ‎ →‎Recommendations for Pharmacologic Management of Patients With Obstructive HCM
23:4523:45, 20 January 2024 diff hist +7,479‎ Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy ‎ /* 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy {{cite journal| author=Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P | display-authors=etal| title=2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. | journal=Circulation | year= 2020 | volu...
02:0702:07, 20 January 2024 diff hist +1‎ Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy ‎ →‎Recommendations for ICD Placement in High-Risk Patients With HCM
02:0702:07, 20 January 2024 diff hist −7‎ Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy ‎ →‎Recommendations for ICD Placement in High-Risk Patients With HCM
02:0602:06, 20 January 2024 diff hist +5,825‎ Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy ‎ /* 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy {{cite journal| author=Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P | display-authors=etal| title=2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. | journal=Circulation | year= 2020 | volu...

16:1016:10, 4 January 2024 diff hist +2,631‎ Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy ‎ /* 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy {{cite journal| author=Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P | display-authors=etal| title=2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. | journal=Circulation | year= 2020 | volu...
15:3215:32, 4 January 2024 diff hist +1‎ Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy ‎ →‎Recommendations for Individuals Who Are Genotype-Positive, Phenotype-Negative
15:3115:31, 4 January 2024 diff hist +1,701‎ Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy ‎ /* 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy {{cite journal| author=Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P | display-authors=etal| title=2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. | journal=Circulation | year= 2020 | volu...

22:0922:09, 7 December 2023 diff hist +5,071‎ Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy ‎ /* 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy {{cite journal| author=Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P | display-authors=etal| title=2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. | journal=Circulation | year= 2020 | volu...
21:5721:57, 7 December 2023 diff hist −33‎ Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy ‎ →‎Recommendation for Exercise Stress Testing
17:0617:06, 7 December 2023 diff hist +1,576‎ Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy ‎ →‎Recommendation for Exercise Stress Testing
16:3316:33, 7 December 2023 diff hist +1,598‎ Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy ‎ /* 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy {{cite journal| author=Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P | display-authors=etal| title=2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. | journal=Circulation | year= 2020 | volu...
16:2816:28, 7 December 2023 diff hist +3‎ Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy ‎ →‎Recommendation for Heart Rhythm Assessment
16:2816:28, 7 December 2023 diff hist +1,653‎ Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy ‎ /* 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy {{cite journal| author=Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P | display-authors=etal| title=2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. | journal=Circulation | year= 2020 | volu...
15:3015:30, 7 December 2023 diff hist −4‎ Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy ‎ →‎Recommendation for Heart Rhythm Assessment
15:2915:29, 7 December 2023 diff hist +4‎ Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy ‎ →‎Recommendation for Heart Rhythm Assessment
15:2915:29, 7 December 2023 diff hist +3,560‎ Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy ‎ /* 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy {{cite journal| author=Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P | display-authors=etal| title=2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. | journal=Circulation | year= 2020 | volu...
15:2215:22, 7 December 2023 diff hist +3,792‎ Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy ‎ /* 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy {{cite journal| author=Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P | display-authors=etal| title=2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. | journal=Circulation | year= 2020 | volu...
15:1415:14, 7 December 2023 diff hist +1‎ Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy ‎ →‎Recommendation for Echocardiography
15:1415:14, 7 December 2023 diff hist −1‎ Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy ‎ →‎Recommendation for Echocardiography
15:1315:13, 7 December 2023 diff hist −546‎ Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy ‎ →‎Recommendation for Echocardiography Tag: Visual edit
15:1215:12, 7 December 2023 diff hist −14‎ Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy ‎ →‎Recommendation for Echocardiography
15:1115:11, 7 December 2023 diff hist −6‎ Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy ‎ →‎Recommendation for Echocardiography
15:1115:11, 7 December 2023 diff hist −141‎ Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy ‎ →‎Recommendation for Echocardiography
15:0915:09, 7 December 2023 diff hist −1‎ Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy ‎ →‎Recommendation for Echocardiography
15:0915:09, 7 December 2023 diff hist +581‎ Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy ‎ →‎Recommendation for Echocardiography
15:0815:08, 7 December 2023 diff hist −3‎ Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy ‎ →‎Recommendation for Echocardiography

User contributions for Edzelco

20 April 2024

18 April 2024

17 April 2024

16 April 2024

15 April 2024

24 March 2024

18 February 2024

16 February 2024

11 February 2024

10 February 2024

7 February 2024

6 February 2024

2 February 2024

1 February 2024

31 January 2024

25 January 2024

23 January 2024

22 January 2024

21 January 2024

20 January 2024

4 January 2024

21 December 2023

7 December 2023

Navigation menu